期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

托伐普坦在心衰治疗中的临床研究进展 被引量：11

Clinical progress of tolvaputan in treating heart failure
在线阅读 下载PDF
导出
摘要 通过查阅托伐普坦的相关文献,系统回顾托伐普坦在心衰治疗中的临床研究进展。临床试验表明,托伐普坦对心衰的治疗具有良好的前景,同时不会损害肾功能,而且其重要的不良反应-饥渴感能被很好地耐受。基于大量临床试验数据,托伐普坦可以为心衰患者提供一种新的治疗选择。 The clinical progress of tolvaputan is reviewed retrospectively by consulting literatures associated with it.Tolvaputan has shown promise for patients with heart failure.It can not decrease renal function and is well tolerated.Tolvaputan may offer a new treatment option for patients with heart failure based on data from available clinical trials.
作者 张炳蓉
机构地区 甘肃省天水市第三人民医院药剂科
出处 《实用药物与临床》 CAS 2011年第2期156-158,共3页 Practical Pharmacy and Clinical Remedies
关键词 托伐普坦 心衰 临床研究 进展 Tolvaputan Heart failure Clinical study Progress
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献11

  • 1Teresa A,Martin M.Vasopressin-receptor antagonists in heart failure[J].Am J Health-Syst Pharm,2008,65(9):807-817.
  • 2Chandrashekhar Y,Prahash AJ,Sen S,et al.The role of arginine vasopressin and its receptors in the normal and failing rat heart[J].J Mol Cell Cardiol,2003,35(5):495-504.
  • 3Gheorghiade M,Niazi I,Ouyang J,et al.Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure:results from a double-blind,randomized trial[J].Circulation,2003,107(21):2690-2696.
  • 4Gheorghiade M,Gattis WA,O′Connor CM,et al.Effects of tolvaptan a vasopressin antagonist,in patients hospitalized with worsening heart failure:a randomized controlled trial[J].JAMA,2004,291(16):1963-1971.
  • 5Udelson JE,Orlandi C,O′Brien T,et al.Vasopressin receptor blockade in patients with congestive heart failure;results from a placebo-controlled,randomized study comparing the effects of tolvaptan,furosemide,and their combination[J].J Am Coll Cardiol,2002,39(suppl A):810.
  • 6Costello-Boerrigter LC,Smith WB,Boerrigter G,et al.Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure[J].Am J Physiol Renal Physiol,2006,290(2):F273-278.
  • 7Udelson JE,McGrew F,Flores E,et al.Multicenter,randomized,double-blind,placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction[J].J Am Coll Cardiol,2007,49(22):2151-2159.
  • 8贾友宏,许莉,田蕾,蒋娟娟,李娜,华丛笑,谢爽,刘红,黄一玲,张阴凤,陈欣,李一石.口服托伐普坦片对男性健康志愿者的药效学作用及其对血电解质的影响[J].中国新药杂志,2008,17(2):160-164. 被引量：17
  • 9Gheorghiade M,Orlandi C,Burnett JC,et al.Rationale and design of the multicenter,randomized,double-blind,placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure:Outcome Study with Tolvaptan(EVEREST)[J].J Card Fail,2005,11(4):260-269.
  • 10Gheorghiade M,Konstam MA,Burnett JC Jr,et al.Short-term clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials[J].JAMA,2007,297(12):1332-1343.

二级参考文献7

  • 1WANG X, GATTONE II V, HARRIS PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat [ J ]. J Am Soc Nephrol, 2005,16 ( 4 ) : 846 - 851.
  • 2GHEORGHIADE M, NIAZI I, OUYANG J, et al. Vasopressin V2- receptor blockade with tolvaptan in patients with chronic heart failure [ J ]. Circulation,2003,107 ( 21 ) :2690 - 2696.
  • 3GHEORGHIADE M, GATTIS WA, O'CONNOR CM,et al. Acute and chronic therapeutic impact of a vasopressin antagonist in congestive heart failure (ACTIV in CHF) investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure a randomized controlled trial (ACTIV inCHF ) [J].JAMA .2004.291 ( 16 ) .1966 - 1971
  • 4ABRAHAM WT,SHAMSHIRSAZ AA ,MCFANN K,et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class Ⅱ and Ⅲ chronic heart failure patients[ J ]. J Am Coil Cardiol,2006,47(8) :1615 - 1621.
  • 5UDELSON JE, SMITH WB, HENDRIX GH, et al. Acute hemodynamic effects of conlvaptan,a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure [ J ]. Circulation ,2001,104 (20) :2417 - 2423.
  • 6KONSTAM MA, GHEORGHIADE M, BURNETT JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators [ J ]. JAMA, 2007,297 ( 12 ) : 1319 - 1331.
  • 7YOSHITAKA Y,SHIGEKI N,SHUJI I,et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats [ J ]. Pharmacology and experimental therapeuticas, 1998,287 (3): 860-867.

共引文献16

同被引文献88

引证文献11

二级引证文献105

实用药物与临床
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部